Document is current
Any future updates will be listed below
-
Authors
Hagelstein, Ilona
Wessling, Laura
Rochwarger, Alexander
Zekri, Latifa
Klimovich, Boris
Tegeler, Christian M.
Jung, Gundram
Schürch, Christian M.
Salih, Helmut R.
Lutz, Martina S. https://orcid.org/0000-0003-2576-2442
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70114180, 70113999)
Wilhelm Sander-Stiftung (2017.100.3)
Deutsche Forschungsgemeinschaft (EXC 2180 - 10084-1_1)
Universitätsklinikum Tübingen
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 17 September 2024
First Online: 4 October 2024
Declarations
:
: The study was approved by IRB (ethics committee of the Faculty of Medicine of the Eberhard Karls Universität Tübingen) at the University Hospital Tübingen and was conducted in accordance with the Declaration of Helsinki; reference numbers 13/2007V, 099/2024BO2. Human material was collected after obtaining informed consent.
: Not applicable.
: GJ, HRS and LZ are listed as inventors on the patent application “Antibodies targeting, and other modulators of, the CD276 antigen, and uses thereof,” EP3822288A1, applicant is German Cancer Research Center, Heidelberg, and Medical Faculty University of Tübingen, Germany.
